<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
03.12.2019 19:51:00

Here's Why Alnylam Pharmaceuticals Rose 35.1% in November

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) gained over 35% last month, according to data provided by S&P Global Market Intelligence. The company surprised investors by earning marketing approval for Givlaari (givosiran) in a rare disease called acute hepatic porphyria only four months after submitting a new drug application (NDA). Investors weren't expecting the U.S. Food and Drug Administration (FDA) to make a decision until the first half of 2020. The announcement forced Wall Street analysts to scramble to update their financial models for the company, which sent the pharma stock soaring. More important, however, is that Givlaari became the first drug based on a targeted RNA interference (RNAi) approach to earn regulatory approval. That's something investors may want to sit up and pay closer attention to.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Alnylam Pharmaceuticals Inc.mehr Analysen

01.10.18 Alnylam Pharmaceuticals Overweight Cantor Fitzgerald
13.08.18 Alnylam Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
07.08.18 Alnylam Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
05.07.18 Alnylam Pharmaceuticals Buy Chardan Capital Markets
04.05.18 Alnylam Pharmaceuticals Hold Stifel, Nicolaus & Co., Inc.

Eintrag hinzufügen

SMI mit neuem Hoch – UBS mit neuem Chef | BX Swiss TV

Aktien in diesem Artikel

Finanzen.net News

pagehit
;